A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib as first-line therapy for advanced non-small cell lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Asahina, H, Yamazaki, K, Kinoshita, I, Sukoh, N, Harada, M, Yokouchi, H, Ishida, T, Ogura, S, Kojima, T, Okamoto, Y, Fujita, Y, Dosaka–akita, H, Isobe, H, Nishimura, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360715/
https://www.ncbi.nlm.nih.gov/pubmed/17047648
http://dx.doi.org/10.1038/sj.bjc.6603393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360715/
https://www.ncbi.nlm.nih.gov/pubmed/17047648
http://dx.doi.org/10.1038/sj.bjc.6603393

Ejemplares similares